Skip to content
Screener

Ocular Therapeutix OCUL Net Change in Cash

Net Change in Cash at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$504.6M+53.2%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$32.75M+334%
KLR
Kalaris TherapeuticsKLRS
-$63.63M-164%
Bausch + Lomb logo
Bausch + LombBLCO
-$118M-16.8%
HRO
HarrowHROW
$21.72M+11.5%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$102.4M

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$1.92B-11.7%
Enterprise value$1.33B-28.4%
P/S36.9×-1.5×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 7:28 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-055256
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Cash flows from financing activities:
Proceeds from exercise of stock options2944,183
Net cash provided by financing activities2944,183
Net (decrease) increase in cash, cash equivalents and restricted cash(70,361)(42,421)
Cash, cash equivalents and restricted cash at beginning of period738,674393,716
Cash, cash equivalents and restricted cash at end of period$668,313$351,295
Supplemental disclosure of cash flow information:
Cash paid for interest$2,189$2,140

Item 1. Financial Statements (unaudited)

FAQ

What is Ocular Therapeutix's net change in cash?
Ocular Therapeutix (OCUL) reported net change in cash of -$70.36M in Q1 2026.
How has Ocular Therapeutix's net change in cash changed year-over-year?
Ocular Therapeutix's net change in cash decreased by 65.9% year-over-year, from -$42.42M to -$70.36M.
What is the long-term trend for Ocular Therapeutix's net change in cash?
Over 3 years (2021 to 2025), Ocular Therapeutix's net change in cash has grown at a 75.4% compound annual growth rate (CAGR), from -$63.89M to $344.96M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Ocular Therapeutix's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude